Plain-English translation of NCT07816185 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new inhaled medication called to see if it can help people who have high blood pressure in the vessels of the lungs, combined with scarring or inflammation of the lung tissue itself. Half of the participants will receive the medication daily for 24 weeks, while the other half will receive a placebo (a non-active inhaler) for the same period. Everyone who completes the first 24 weeks can then continue receiving the medication in an extended phase.
People with both lung scarring and high blood pressure in their lung vessels have limited treatment options and often struggle with breathing and physical activity. This trial is testing whether this medication can help improve symptoms and reduce the strain on the heart and lungs in this group of patients.
You likely qualify if…
You likely don't qualify if…
You will visit the trial site regularly over 24 weeks and use your assigned inhaler (either the medication or placebo) every day at home. The study team will monitor your breathing, physical activity, and overall health throughout this period. If you complete the initial 24 weeks, you'll have the opportunity to continue in an extension phase where everyone receives the active medication, allowing researchers to gather longer-term safety and benefit information.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
United States